315 related articles for article (PubMed ID: 35287627)
1. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
Guo Y; Ren Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
BMC Cancer; 2022 Mar; 22(1):270. PubMed ID: 35287627
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
3. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
[No Abstract] [Full Text] [Related]
4. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
5. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
[TBL] [Abstract][Full Text] [Related]
6. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
[TBL] [Abstract][Full Text] [Related]
7. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
Wang X; Yang Y
Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
[TBL] [Abstract][Full Text] [Related]
8. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
Hou C; Xiong B; Zhou L; Fei Y; Shi C; Zhu X; Xie T; Wu Y
BMC Cancer; 2024 Mar; 24(1):387. PubMed ID: 38539150
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
[TBL] [Abstract][Full Text] [Related]
11. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study.
Xi T; Lai EC; Min AR; Shi LH; Wu D; Xue F; Wang K; Yan Z; Xia Y; Shen F; Lau WY; Wu MC
Hepatogastroenterology; 2012 Jun; 59(116):1198-203. PubMed ID: 22580673
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
Liu C; Sun L; Xu J; Zhao Y
World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
[TBL] [Abstract][Full Text] [Related]
14. Chemoembolization of recurrent hepatoma after curative resection: prognostic factors.
Zu QQ; Liu S; Zhou CG; Yang ZQ; Xia JG; Zhao LB; Shi HB
AJR Am J Roentgenol; 2015 Jun; 204(6):1322-8. PubMed ID: 26001244
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
[TBL] [Abstract][Full Text] [Related]
16. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.
Shi X; Wang Y; Ren J; Han X; Bi Y
BMC Cancer; 2023 Nov; 23(1):1144. PubMed ID: 38001447
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
19. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study.
Zhang Q; Wang Y; Zhang J; Zhang W; Gong J; Ma R
Technol Cancer Res Treat; 2021; 20():15330338211060180. PubMed ID: 34855560
[No Abstract] [Full Text] [Related]
20. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]